Komodo

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
화요일, 5월 7, 2024

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

Key Points: 
  • Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
  • Research and development expenses for the quarter ended March 31, 2024, were $13.0 million, compared to $8.1 million in the previous quarter.
  • The increase was primarily due to expenses incurred to initiate the new clinical trials.
  • General and administrative expenses for the quarter ended March 31, 2024 were $6.8 million, similar to the $6.9 million incurred in the previous quarter.

Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024

Retrieved on: 
월요일, 5월 6, 2024

Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.

Key Points: 
  • Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.
  • The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.
  • Komodo Health researchers studied the differences in patient outcomes for pregnant women who continued or discontinued the use of antidepressants during pregnancy.
  • Komodo Health researchers analyzed whether the COVID-19 pandemic exacerbated inequities in breast cancer care through its impact on breast cancer staging and HCRU.

Simplified IT Consulting Proudly Unveils its Newest Member: Koko, the Tech-Savvy Komodo Dragon Mascot

Retrieved on: 
금요일, 5월 3, 2024

WOODLAND HILLS, Calif., May 3, 2024 /PRNewswire/ -- Simplified IT Consulting, a Managed Service Provider (MSP) supporting small to medium-sized businesses, proudly unveils its newest member: Koko, a charismatic mascot inspired by the majestic Komodo dragon.

Key Points: 
  • WOODLAND HILLS, Calif., May 3, 2024 /PRNewswire/ -- Simplified IT Consulting, a Managed Service Provider (MSP) supporting small to medium-sized businesses, proudly unveils its newest member: Koko, a charismatic mascot inspired by the majestic Komodo dragon.
  • "As Simplified IT Consulting continues to evolve in the digital age, we sought a mascot that could bridge the gap between tradition and innovation.
  • "Koko symbolizes the essence of Simplified IT Consulting, embracing simplicity, fostering innovation and collaboration, and promoting continuous learning.
  • Stay tuned for more updates as we unleash the power of Koko, the tech-savvy Komodo dragon, upon the world!

GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset

Retrieved on: 
화요일, 4월 23, 2024

STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.

Key Points: 
  • STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.
  • The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment.
  • “The partnership between GeneDx and Komodo Health represents a milestone in advancing the understanding of rare disease and its associated drug development”, said Melanie Duquette, Chief Growth Officer, GeneDx.
  • GeneDx is continuing to showcase its value to biopharma companies through its participation in the World Orphan Drug Congress meeting in Boston, April 23-25th.

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

Retrieved on: 
수요일, 4월 10, 2024

San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams.
  • Komodo’s data and technology applications will support MoonLake’s in-depth market research, clinical trial site selection, go-to-market strategies, and patient journey mapping – all aimed at accelerating the development of new treatment options and improving outcomes for patients with inflammatory skin and joint diseases.
  • Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Retrieved on: 
수요일, 4월 10, 2024

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.

Key Points: 
  • MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
  • View the full release here: https://www.businesswire.com/news/home/20240410438883/en/
    Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision-making across its clinical operations, medical, marketing, and market access teams.
  • Tino Anthamatten, VP, Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors.
  • The real-world insights from Komodo helped validate a future HS market size projected to exceed $10B by 2035.

Celebrities routinely drop in on this Florida university’s hospitality course

Retrieved on: 
목요일, 4월 25, 2024

Uncommon Courses is an occasional series from The Conversation U.S. highlighting unconventional approaches to teaching. Title of course: “The David Grutman Experience”What prompted the idea for the course?When David clarified that he wanted to teach an entire course on entrepreneurship – drawing from his own experiences – I thought it would be a great opportunity.

Key Points: 


Uncommon Courses is an occasional series from The Conversation U.S. highlighting unconventional approaches to teaching.

Title of course:


“The David Grutman Experience”

What prompted the idea for the course?

  • When David clarified that he wanted to teach an entire course on entrepreneurship – drawing from his own experiences – I thought it would be a great opportunity.
  • Naively, I started sharing tips on how to run the class, based on Florida International University’s academic framework.
  • Similarly, Bad Bunny told students he cannot work on a project without feeling the passion and identifying with it.
  • His last class in spring of 2024 had 400-plus students – so many that we had to use a ballroom as his classroom.

What does the course explore?


David focuses on the cornerstones of success in hospitality: authenticity, relationships, taking it personally, the pros and cons of first-generation versus second-generation establishments, picking a niche, work-life balance and much more. He also goes in depth and shares his business successes as well as failures.

What’s a critical lesson from the course?

  • The strongest and most lasting lesson is probably about tenacity and not giving up.
  • For instance, David shared stories of his successes as much as he shared stories of his failures.
  • In each of those cases, David shared what he learned from the failures and how he avoided the same mistakes going forward.

What will the course prepare students to do?

  • This lesson underlined the importance of collaboration and constructive feedback in entrepreneurship.
  • He emphasized aligning with personal values to establish credibility and attract partnerships, which fosters community engagement and ecosystem growth.


Michael Cheng does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

OVARIAN CANCER RESEARCH ALLIANCE LAUNCHES INNOVATIVE "FIND A DOCTOR" TOOL TO EMPOWER PATIENTS NATIONWIDE

Retrieved on: 
화요일, 4월 9, 2024

NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Ovarian Cancer Research Alliance (OCRA) proudly unveiled its latest innovation in supporting individuals affected by ovarian and other gynecologic cancers: the "Find a Doctor" tool.

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Today, Ovarian Cancer Research Alliance (OCRA) proudly unveiled its latest innovation in supporting individuals affected by ovarian and other gynecologic cancers: the "Find a Doctor" tool.
  • Navigating a diagnosis of ovarian or other gynecologic cancer can be overwhelming, and finding the right medical team is paramount to ensuring the best possible outcomes.
  • "Access to quality care is a critical issue of equity for patients," said Audra Moran, President and CEO of OCRA.
  • The new tool underscores OCRA's ongoing commitment to advancing research, raising awareness, and providing support to the ovarian cancer community.

Axiom Health Expands Leadership Team to Accelerate Growth

Retrieved on: 
목요일, 3월 28, 2024

These appointments strengthen Axiom Health's leadership capabilities as the company seeks to expand its market presence and deliver enhanced value to its clients.

Key Points: 
  • These appointments strengthen Axiom Health's leadership capabilities as the company seeks to expand its market presence and deliver enhanced value to its clients.
  • His expertise in healthcare technology and his track record of driving innovation will be instrumental in guiding Axiom Health's growth trajectory.
  • Mr. Best joins Axiom Health as CCO with over two decades of experience in the healthcare industry, including sales and marketing leadership roles at Stryker, Integra Lifesciences, TriMed and Komodo Health.
  • "We are excited to welcome Rusty and Jim to the Axiom Health team," said Jim Hinrichs, Chairman of the Board.

Healthcare Analytics Market Size to Grow by USD 66.54 billion from 2024 to 2028, Market growth at 24.79% CAGR expected during the forecast period, Technavio

Retrieved on: 
목요일, 3월 14, 2024

The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.

Key Points: 
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.
  • The Healthcare Analytics Market is experiencing significant growth driven by advancements in healthcare data analytics, which encompass clinical, predictive, prescriptive, and descriptive analytics.
  • The Healthcare Analytics Market is witnessing substantial growth driven by advancements in healthcare data analytics, encompassing clinical, predictive, prescriptive, and descriptive analytics.
  • Emerging technologies drive market opportunities amidst challenges, positioning the healthcare analytics market for substantial growth and dynamic evolution.